Chicago, IL – December 04, 2015 – Today, Zacks Equity Research discusses the MedTech (Part 1), including Bayer AG, Abbott Laboratories, Roche Holding AG, Medtronic plc, and Johnson & Johnson.
Impressive Prospects Ahead
According to a survey by EvaluateMedTech World Preview, the MedTech space is positioned for impressive growth in the near term. This should compel investors to keep an eye out on the sector that is generally not in the limelight from the investment perspective.
At a glance, Medtech sales worldwide are expected to grow at a CAGR of 4.1% to $478 billion by 2020. Steering ahead of Cardiology and Diagnostics, In Vitro Diagnostics (IVD) is expected to emerge as the sector leader. Neurology, meanwhile, holds promise as the fastest growing division among the top 15 segments by 2020. On the other hand, Orthopedics, which is already going downhill, may prove to be one of the slowest growing segments in 2020 with a CAGR of 3.2% per year.
Changing Trends in MedTech
Investors interested in the Medical Devices industry generally keep analyzing existing trends – like longer life expectancies, mergers and acquisitions, emerging market opportunities, increased regulatory scrutiny and health care reforms. However, here are some of the emerging trends that one should also take into account, as these might eventually transform the prospects of the industry.
Evolving Home Medical Devices Market: With growing awareness, self-health care has become one of the driving forces within the home medical devices market. A recent report published in mddionline.com states that the global home healthcare market will reach $303.6 billion by 2020, up over 70% from $176.1 billion in 2013.
READ MORE HERE